echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Injecting naloxone Zimhi receives FDA approval to treat opioid overdose

    Injecting naloxone Zimhi receives FDA approval to treat opioid overdose

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    The stock price of Adamis Pharmaceuticals has risen by 31% a few days ago.


    Zimhi is a 5 mg/0.


    It should be pointed out that this is the third attempt by Adamis after two complete response letters (CRL), and the drug has been approved


    Compared with other drugs that require nasal or intramuscular injection, among currently available products, Zimhi can provide patients with the highest level of naloxone throughout the body


    It should be noted that Zimhi is only suitable for people who overdose opioids, so it has no effect on people who do not take these drugs.


    Reference source: At Last, FDA Signs Off on Adamis' Opioid Overdose Drug

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.